Grass Pollen Allergy Vaccine Successful In Phase IIa Trial

<p>Main Category: Allergy
Also Included In: Immune System / Vaccines
Article Date: 16 Jun 2012 0:00 PDT</p>

<p> email to a crony   printer accessible   opinions   </p>

<p>! rate article
Patient / Public:
Healthcare Prof:</p>

<p>A novel vaccine for weed pollen allergy has shown poignant improvements for patients in a Phase IIa trial. The vaccine BM32 is formed on an innovative recombinant peptide conduit record that allows for fewer injections and shows fewer side effects compared with other immunotherapy treatments for allergy sufferers. BM32 has been grown by Biomay AG, an Austrian biopharmaceutical association specialized in a find and growth of innovative allergy therapeutics. The association has already instituted a Phase IIb hearing for BM32 with 180 allergic patients.</p>

<p>Biomay AG announced currently earnest formula from a First-in-Man Phase IIa hearing with a innovative allergy vaccine BM32. The vaccine significa...